Clinical experience with monoclonal antibodies to epidermal growth factor receptor

被引：18

作者：

Calvo E. ^{[1
]}

Rowinsky E.K. ^{[1
]}

机构：

[1] Institute for Drug Development, Cancer Therapy and Research Center, University of Texas, San Antonio, TX 78229

来源：

Current Oncology Reports | 2005年 / 7卷 / 2期

关键词：

Epidermal Growth Factor Receptor; Cetuximab; Epidermal Growth Factor Receptor Expression; Panitumumab; Proc ASCO;

D O I：

10.1007/s11912-005-0034-9

中图分类号：

学科分类号：

摘要：

Recent knowledge about the intermediate steps and final consequences of ligand-dependent epidermal growth factor receptor (EGFR) activation has clearly supported the notion that EGFR plays a fundamental role in regulating the proliferation and survival of malignant neoplasms. Among the rationally designed target-based therapeutics that are being assessed, those targeting EGFR appear to be some of the most clinically relevant. The strategy of using monoclonal antibodies (mAbs) to block ligand binding to the extracellular domain of the EGFR has led to the development of therapeutics that robustly arrest malignant cell proliferation and, in some cases, induce profound tumor regression. The chimeric mAb against EGFR, cetuximab, has already been approved by regulatory agencies worldwide to treat patients with advanced colorectal cancer. Other mAbs against EGFR, particularly panitumumab (ABX-EGF), h-R3, and EMD72000, are in advanced stages of clinical development. Copyright © 2005 by Current Science Inc.

引用

页码：96 / 103

页数：7

共 58 条

[31] Trigo J., Hitt R., Koralewski P., Et al., Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study, Proc. ASCO, 23, (2004)
[32] Bonner J.A., Giralt J., Harari P.M., Et al., Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: Phase III study of high dose radiation therapy with or without cetuximab, Proc. ASCO, 23, (2004)
[33] Rosell R., Daniel C., Ramlau R., Et al., Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC), Proc. ASCO, 23, (2004)
[34] Abbruzzese J.L., Rosenberg A., Xiong H.Q., Et al., Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer, Proc. ASCO, 20, (2001)
[35] Bier H., Hoffmann T., Haas I., van Lierop A., Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck, Cancer Immunol. Immunother., 46, pp. 167-173, (1998)
[36] Tabernero J., Rojo F., Jimenez E., Et al., A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors, Proc. ASCO, 22, (2003)
[37] Vanhoefer U., Tewes M., Rojo F., Et al., Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor, J. Clin. Oncol., 22, pp. 175-184, (2004)
[38] Bier H., Hoffmann T., Hauser U., Et al., Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx, Cancer Chemother. Pharmacol., 47, pp. 519-524, (2001)
[39] Morales-Morales A., Duconge J., Caballero-Torres I., Et al., Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma, Nucl. Med. Biol., 26, pp. 275-279, (1999)
[40] Crombet T., Osorio M., Cruz T., Et al., Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients, J. Clin. Oncol., 22, pp. 1646-1654, (2004)

← 1 2 3 4 5 6 →